Work

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies

Year: 2008

Type: conference-abstract

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(08)72329-2

Authors: A. Tse, S. Yazji, A. Naing, D. Matthews, G. Schwartz, K. Lawhorn, R. Kurzrock

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2047413968

Cites:

Cited by: 3

Related to: 10